Evaluating Adjuvant Pembrolizumab for Triple-Negative Breast Cancer Post-Chemotherapy
Medical experts preview upcoming clinical trial data examining whether post-surgery immunotherapy can lower recurrence risks for high-risk breast cancer patients.
🧠AI AnalysisPhoto: medpagetoday.com
Key points
- Phase III SWOG-S1418/NRG Oncology BR006 trial explores adjuvant pembrolizumab
- Focuses on triple-negative breast cancer patients with residual disease post-chemotherapy
- Weighs recurrence-free survival against potential permanent immune-related toxicities
An upcoming presentation at the San Antonio Breast Cancer Symposium is set to shed light on whether adding the immunotherapy drug pembrolizumab, marketed as Keytruda, after surgery can improve outcomes for patients with triple-negative breast cancer who still have residual disease following neoadjuvant chemotherapy. Rena Callahan, MD, of UCLA Health Santa Clarita Cancer Care, discussed the phase III SWOG-S1418/NRG Oncology BR006 trial in a recent interview, highlighting questions surrounding postoperative anti-PD-1/PD-L1 therapy efficacy.
While preoperative immunotherapy has previously demonstrated improvements in pathologic complete response rates and event-free survival, the effectiveness of continuing such treatment post-surgery has remained uncertain. Previous trials involving other agents, such as avelumab in the A-BRAVE study, did not show a clear benefit, leaving clinicians to rely primarily on standard options like capecitabine or targeted therapy for specific BRCA mutations. This new trial specifically investigates high-risk individuals with residual tumors measuring at least a centimeter, irrespective of their initial PD-L1 status.
Evaluating the balance between therapeutic gains and potential immune-related adverse events remains a critical component of the upcoming findings. Researchers plan to examine specific patient subgroups based on nodal burden and biomarker expression to better understand who might benefit most. Because checkpoint inhibitors can sometimes trigger long-lasting toxicities such as pneumonitis, endocrinopathies, or diabetes, weighing these risks carefully is essential for patient counseling.
What to know: The upcoming trial results aim to clarify if postoperative pembrolizumab reduces recurrence rates for high-risk triple-negative breast cancer patients, though clinicians must carefully weigh potential long-term immune-related toxicities. Always consult a qualified oncologist for personalized medical decisions.
Source medpagetoday.com — medpagetoday.com/meetingcoverage/sabcsfuturefocus/123901 ↗
Read next
🏃FitnessUnderstanding and Addressing Love Handles Through Lifestyle Changes
Experts clarify that spot reduction of fat is not physiologically possible, recommending a combination of calorie management and high-intensity interval training instead.
🏃FitnessCiele Releases New Woolmark-Certified Merino Winter Running Apparel
Montreal-based brand Ciele has launched its second collection of merino wool running gear, featuring performance-focused fabrics designed for cold-weather training.
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.